Compare WAT & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAT | KVUE |
|---|---|---|
| Founded | 1958 | 2022 |
| Country | United States | United States |
| Employees | 7900 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 32.9B |
| IPO Year | 1996 | 2023 |
| Metric | WAT | KVUE |
|---|---|---|
| Price | $341.82 | $17.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $379.19 | $19.45 |
| AVG Volume (30 Days) | 1.1M | ★ 17.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | 0.47 | ★ 40.74 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $104.66 | $4.85 |
| Revenue Next Year | $10.40 | $2.63 |
| P/E Ratio | ★ N/A | $69.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $275.05 | $14.02 |
| 52 Week High | $414.15 | $24.00 |
| Indicator | WAT | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 54.07 |
| Support Level | $340.09 | $16.89 |
| Resistance Level | $356.41 | $17.85 |
| Average True Range (ATR) | 11.97 | 0.34 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 53.79 | 62.84 |
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.